Introduction The efficacy of Adalimumab (ADA) in ulcerative colitis (UC) has been demonstrated in controlled trials. However there is little information on the real data of steroid free remission within UK clinical practice.
Method This was a retrospective multicentre cohort study of 4 hospital Trusts within the NorthWest region of the UK. Demographic data, concomitant therapy, CRP and faecal calprotectin were recorded at baseline. Baseline glucocorticosteroids (GS) was compared at week 8 and 12 and 6 month outcomes following induction of ADA, 160 mg, 80 mg, 40 mg EOW.
Results43 patients were identified from the 4 sites who received a minimum of 12 weeks treatment. Of these 26 were on GS at induction. 3 patients remained on GS at week 8 and all patients were steroid free at week 12. There was 6 month data on 15 of the 43 patients that had received ADA. 6 of 15 patients had discontinued ADA by 6 months of treatment with 1 skin infection and 5 loss of response with 1 requiring colectomy. Number of males (%) was 27 (63%), median age (SD) (range) 54 yrs (16.3) (20–74yrs).
Conclusion Real life data of ADA within this cohort demonstrates that all the patients were steroid free at week 12 with only just over half (60%) continued ADA beyond 6 months.
Disclosure of interest K. Kemp Speaker Bureau of: Abbvie, MSD, Takaeda, Actavis, Dr Falk, D. Byrne: None Declared, R. Campbell: None Declared, T. Law Speaker Bureau of: MSD, W. McManus: None Declared, R. Willert Speaker Bureau of: Abbvie, MSD, Takaeda.